Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Ebiomedicine|September 11, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cellsHiroshi Takata, Juyeon C Kakazu, Julie L Mitchell, et al.
Journal of Virology|November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and PotencyDavid Easterhoff, Justin Pollara, Kan Luo, et al.
JCI Insight|May 8, 2023
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination aloneMargaret C Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 2, 2024
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national studyFaris G Bakri, Heyam H Mukattash, Hiam Esmeiran, et al.
The Journal of Clinical Investigation|November 11, 2021
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infectionJulie L Mitchell, Justin Pollara, Kenneth Dietze, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
Nature Communications|May 29, 2025
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohortsPhilip K Ehrenberg, Aviva Geretz, Meta Volcic, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Pageof 13